Pfizer’s Talzenna cleared for breast cancer
US regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with breast cancer carrying a certain mutation, identified by a companion diagnostic developed by Myriad.
Read More
Tag: Medivation
Pfizer swoops in to grap Medivation for $14bn
Following weeks of speculation Pfizer has stepped forward with a $14-billion bid for Medivation, beating Sanofi and other suitors to the finish line in a move designed to boost its oncology portfolio.
Read More
Merck joins the pack circling Medivation
Merck & Co is reportedly the latest pharma to consider snapping up US cancer biotech Medivation.
Read More
Sanofi moves to replace Medivation board
Sanofi is gearing up to challenge Medivation’s Board of Directors on the grounds that it has thus far rebuffed any attempts to discuss its proposed takeover of the firm.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
